Childhood Esthesioneuroblastoma Treatment (PDQ®)–Health Professional Version
SECTIONS
- Incidence
- Histology and Molecular Features
- Clinical Presentation
- Prognostic Factors
- Stage Information for Childhood Esthesioneuroblastoma
- Treatment and Outcome of Childhood Esthesioneuroblastoma
- Treatment Options Under Clinical Evaluation for Childhood Esthesioneuroblastoma
- Special Considerations for the Treatment of Children With Cancer
- Changes to This Summary (09/21/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (09/21/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
This summary was comprehensively reviewed and reformatted.
Added text to state that in a retrospective, multi-institutional review of 24 pediatric patients with esthesioneuroblastoma, the median age at presentation was 14 years and 75% of patients were female (cited Venkatramani et al. as reference 8).
Added this new section.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
.png)
No hay comentarios:
Publicar un comentario